Literature DB >> 32158052

Medications for Opioid Use Disorder: A Guide for Physicians.

Naazia Azhar1, Ravikumar Chockalingam1, Asad Azhar1.   

Abstract

The opioid crisis has shaped the national public health dialogue for some time now. A "call to action" is a strong and resounding cry from multiple disciplines. This piece intends to detail the nuts and bolts of prescribing medications used for the treatment of opioid use disorder. The underlying message here is that opioid use disorder is a chronic, treatable illness and physicians of all specialties have a responsibility to not turn a blind eye. Copyright 2020 by the Missouri State Medical Association.

Year:  2020        PMID: 32158052      PMCID: PMC7023948     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  27 in total

1.  Safety of the newer class of opioid antagonists in pregnancy.

Authors:  Shirley Poon; Anna Pupco; Gideon Koren; Pina Bozzo
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

2.  Adverse effects in children after unintentional buprenorphine exposure.

Authors:  Ann-Jeannette Geib; Kavita Babu; Michele Burns Ewald; Edward W Boyer
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

3.  Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Authors:  David A Fiellin; Richard S Schottenfeld; Christopher J Cutter; Brent A Moore; Declan T Barry; Patrick G O'Connor
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873

4.  QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.

Authors:  Judith A Martin; Anthony Campbell; Thomas Killip; Margaret Kotz; Mori J Krantz; Mary Jeanne Kreek; Brian A McCarroll; Davendra Mehta; J Thomas Payte; Barry Stimmel; Trusandra Taylor; Mark C P Haigney; Bonnie B Wilford
Journal:  J Addict Dis       Date:  2011-10

5.  Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Authors:  George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala
Journal:  JAMA       Date:  2008-11-05       Impact factor: 56.272

6.  Overdose after detoxification: a prospective study.

Authors:  James D Wines; Richard Saitz; Nicholas J Horton; Christine Lloyd-Travaglini; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2007-02-05       Impact factor: 4.492

7.  Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Elizabeth Evans; David Huang; Robert Weiss; Andrew Saxon; Kathleen M Carroll; George Woody; David Liu; Paul Wakim; Abigail G Matthews; Mary Hatch-Maillette; Eve Jelstrom; Katharina Wiest; Paul McLaughlin; Walter Ling
Journal:  Addiction       Date:  2016-01-13       Impact factor: 6.526

8.  Home buprenorphine/naloxone induction in primary care.

Authors:  Joshua D Lee; Ellie Grossman; Danae DiRocco; Marc N Gourevitch
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

Review 10.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Authors:  Luis Sordo; Gregorio Barrio; Maria J Bravo; B Iciar Indave; Louisa Degenhardt; Lucas Wiessing; Marica Ferri; Roberto Pastor-Barriuso
Journal:  BMJ       Date:  2017-04-26
View more
  1 in total

1.  Enhancement of a Heroin Vaccine through Hapten Deuteration.

Authors:  Tyson F Belz; Paul T Bremer; Bin Zhou; Beverly Ellis; Lisa M Eubanks; Kim D Janda
Journal:  J Am Chem Soc       Date:  2020-07-27       Impact factor: 15.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.